Showing Grants 1 to 10 of 30 |
| A Developing Story: HIV Resistance Among African Populations May be Linked to Genotypic Traits of Type 2 Diabetes |
| | Elijah Songok, Kenya Medical Research Institute, Nairobi, Kenya - KE |
|
| |
| |
Elijah Songok at the Kenya Medical Research Institute hopes to better understand preliminary findings from studies of sex workers that natural resistance to HIV may be linked to genetic markers for type 2 diabetes.
|
| A Mutable Vaccine for HIV |
| | Marilia Cascalho, University of Michigan, Ann Arbor, MI, United States - US |
|
| |
| |
Marilia Cascalho of the University of Michigan will test whether a “mutable”DNA vaccine in which the gene coding for the antigen mutates a million times more frequently than a typical gene will trigger immune response that anticipates the production of new viral variants and produces broadly neutralizing antibodies against HIV. |
| A Novel Approach to Prevent or Cure HIV Infection |
| | Karthikeyan Kandavelou, Pondicherry Biotech Pvt Ltd, Pondicherry, India - IN |
|
| |
| |
People born with a natural resistance to the HIV virus have a genetic mutation in the CCR5 gene. Karthikeyan Kandavelou of Pondicherry Biotech Pvt. Ltd. in India will attempt to achieve targeted disruption of CCR5 genes, making an important first step in a new strategy to make people permanently resistant to HIV. |
| A Targeted Stealth Weapon of Viral Destruction for HIV |
| | Karen Anderson, Yale University, New Haven, CT, United States - US |
|
| |
| |
HIV has a very high rate of mutation allowing it to very rapidly develop resistance to AIDS therapies. The essential viral enzyme, HIV reverse transcriptase, lacks a "proofreading" or "repair activity" leading to errors or mutations. Karen Anderson of Yale University is working on "stealth" compounds that have a unique anchor specific for HIV. These compounds encourage the virus to make mutations until the virus is annihilated. |
| Alternative Strategies to Eradicate the Latent HIV-1 Reservoir |
| | Olaf Kutsch, University of Alabama , Birmingham, AL, United States - US |
|
| |
| |
Olaf Kutsch of the University of Alabama proposes that HIV latency is controlled by host-gene promoter interference, a mechanism that prevents the initiation of viral gene expression. Understanding how host-gene promoter interference controls latent HIV-1 infection may aid development of therapies to deplete latent HIV in patients. |
| An Innovative Strategy to Induce Potent Mucosal Immune Responses Against HIV |
| | Yue Chen, University of Pittsburgh, Pittsburgh, PA, United States - US |
|
| |
| |
Yue Chen of the University of Pittsburgh will attempt to develop an oral HIV vaccine based on Clostridium perfringens, a bacteria able to withstand upper GI conditions to deliver large amounts of antigens to gut-associated lymphoid tissue, a major site of HIV activity. |
| Antibodies to GB Virus C Envelope Glycoprotein E2 Delay HIV Disease Progression |
| | Jinhua Xiang, University of Iowa, Iowa City, IA, United States - US |
|
| |
| |
To test the hypothesis that immunization with a non-HIV antigen will neutralize the virus, Jinhua Xiang of the University of Iowa will determine if immunization with an envelope protein of the GB Virus C elicits antibodies that block HIV replication. |
| Antibody-Dependent Cellular Cytotoxicity Targeted Against HIV-1 Env Glycans |
| | Pandelakis Koni, Medical College of Georgia, Augusta, GA, United States - US |
|
| |
| |
Pandelakis Koni of the Medical College of Georgia will study the complex sugar coating that surrounds and protects HIV to see if parts of this shield can serve as targets for a vaccine, to generate antibodies that bind to and accelerate the killing of HIV-infected cells. |
| Autoantibody Protection Against HIV Infection |
| | Benjamin Chain, University College London, London, United Kingdom - GB |
|
| |
| |
Benjamin Chain of University College London will attempt to stimulate an antibody response against CCR5, a protein found in the body which is used by HIV to infect cells. By combining a small portion of the molecule with part of the tetanus bacterium, Chain hopes to overcome natural tolerance of CCR5 to deplete the presence of the protein and prevent a way for HIV to enter cells. |
| Autophagy as a Cell-Autonomous Mechanism of HIV Control |
| | Vojo Deretic, University of New Mexico, Albuquerque, NM, United States - US |
|
| |
| |
Vojo Deretic of the University of New Mexico proposes that authophagy, the process by which cells destroy cellular components and intracellular pathogens, can be induced through drug therapy to not only destroy the HIV virus in infected cells, but to also block its transmission from dendritic to T cells. |